We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.
- Authors
Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; Bakuli, A.; Amin, A.; Gurbanov, K.; Salles, G.
- Abstract
Encore Abstract - previously submitted to AACR 2023 The research was funded by: MorphoSys AG Keyword: Aggressive B-cell non-Hodgkin lymphoma B Conflicts of interests pertinent to the abstract. b B J. Duell b Research funding: MorphoSys AG, Regeneron B P. Abrisqueta b Consultant or advisory role: Janssen, Celgene, AbbVie, AstraZeneca Honoraria: Janssen, Celgene, AbbVie, AstraZeneca, Gilead Other remuneration: Speakers' bureau: Janssen, Celgene, AbbVie, AstraZeneca, Gilead B M. Andre b Research funding: Roche, Johnson & Johnson, Takeda Educational grants: Roche, Bristol-Myers-Squib, Celgene, Gilead, AbbVie, AstraZeneca Other remuneration: Advisory board: Takeda, Bristol-Myers-Squibb, Karyopharm, Gilead, Incyte. B Introduction: b Tafasitamab, an anti-CD19 immunotherapy that enhances antibody-dependent cellular cytotoxicity and phagocytosis, received accelerated approval in the USA and conditional authorization in Europe in combination with lenalidomide (LEN) for patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) based on the results of the open-label, multicenter, single-arm, Phase II L-MIND study (NCT02399085; Salles G., et al.
- Subjects
DIFFUSE large B-cell lymphomas; PATIENT safety; ANTIBODY-dependent cell cytotoxicity; CURATIVE medicine
- Publication
Hematological Oncology, 2023, Vol 41, p437
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_323